Intensive care protocol aims to tame brain hemorrhage in first critical hours

NCT ID NCT06648369

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial investigates a 'maximal medical treatment' bundle for people with intracerebral hemorrhage (bleeding in the brain). The bundle includes rapid blood pressure control, reversal of blood thinners, and a drug to reduce bleeding, all delivered within the first 72 hours in a high-dependency unit. The study enrolls adults with non-traumatic brain bleeding within 6 hours of symptom onset and aims to see if this intensive approach is feasible and safe. If it works, it could lead to better outcomes for a condition that currently has limited treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MAX-ICH care bundle (intensive blood pressure control, anticoagulation reversal, tranexamic acid)

What this could lead to

If successful, this approach could become a standard treatment to reduce disability and death from intracerebral hemorrhage.

What could go wrong

This is a small pilot study focused on feasibility, not yet on proving effectiveness. The intensive protocol may be difficult to implement in all hospitals.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRA CEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Inselspital, University Hospital Bern

    RECRUITING

    Bern, 3010, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••